Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Overview

Journal Neurocrit Care

Specialty Critical Care

Date 2024 May 20

PMID 38769253

Authors

Emma Andersson

Martin Ost

Keti Dalla

Henrik Zetterberg

Kaj Blennow

Bengt Nellgard

Affiliations

Soon will be listed here.

Abstract

Background: This study investigated trajectory profiles and the association of concentrations of the biomarkers neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in ventricular cerebrospinal fluid (CSF) with clinical outcome at 1 year and 10-15 years after a severe traumatic brain injury (sTBI).

Methods: This study included patients with sTBI at the Neurointensive Care Unit at Sahlgrenska University Hospital, Gothenburg, Sweden. The injury was regarded as severe if patients had a Glasgow Coma Scale ≤ 8 corresponding to Reaction Level Scale ≥ 4. CSF was collected from a ventricular catheter during a 2-week period. Concentrations of NfL and GFAP in CSF were analyzed with enzyme-linked immunosorbent assay. The Glasgow Outcome Scale (GOS) was used to assess the 1-year and 10-15-year outcomes. After adjustment for age and previous neurological diseases, logistic regression was performed for the outcomes GOS 1 (dead) or GOS 2-5 (alive) and GOS 1-3 (poor) or GOS 4-5 (good) versus the independent continuous variables (NfL and GFAP).

Results: Fifty-three patients with sTBI were investigated; forty-seven adults are presented in the article, and six children (aged 7-18 years) are described in Supplement 1. The CSF concentrations of NfL gradually increased over 2 weeks post trauma, whereas GFAP concentrations peaked on days 3-4. Increasing NfL and GFAP CSF concentrations increased the odds of GOS 1-3 outcome 1 year after trauma (odds ratio [OR] 1.73, 95% confidence interval [CI] 1.07-2.80, p = 0.025; and OR 1.61, 95% CI 1.09-2.37, p = 0.016, respectively). Similarly, increasing CSF concentrations of NfL and GFAP increased the odds for GOS 1-3 outcome 10-15 years after trauma (OR 2.04, 95% CI 1.05-3.96, p = 0.035; and OR 1.60, 95% CI 1.02-2.00, p = 0.040).

Conclusions: This study shows that initial high concentrations of NfL and GFAP in CSF are both associated with higher odds for GOS 1-3 outcome 1 year and 10-15 years after an sTBI, implicating its potential usage as a prognostic marker in the future.

Citing Articles

Administration of anti-GFAP antibodies increases CGRP expression and increases pain hypersensitivity in spinal cord injured animals.

Hergenroeder G, Molina S, Herrera J Int J Immunopathol Pharmacol. 2025; 39:3946320251320754.

PMID: 40019103 PMC: 11873870. DOI: 10.1177/03946320251320754.

References

Nylen K, Ost M, Csajbok L, Nilsson I, Hall C, Blennow K . Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien). 2008; 150(3):221-7. DOI: 10.1007/s00701-007-1489-2. View

Grande P . The "Lund Concept" for the treatment of severe head trauma--physiological principles and clinical application. Intensive Care Med. 2006; 32(10):1475-84. DOI: 10.1007/s00134-006-0294-3. View

Andersson E, Rackauskaite D, Svanborg E, Csajbok L, Ost M, Nellgard B . A prospective outcome study observing patients with severe traumatic brain injury over 10-15 years. Acta Anaesthesiol Scand. 2017; 61(5):502-512. DOI: 10.1111/aas.12880. View

Agoston D, Shutes-David A, Peskind E . Biofluid biomarkers of traumatic brain injury. Brain Inj. 2017; 31(9):1195-1203. DOI: 10.1080/02699052.2017.1357836. View

Shahim P, Gren M, Liman V, Andreasson U, Norgren N, Tegner Y . Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016; 6:36791. PMC: 5098187. DOI: 10.1038/srep36791. View

Ost M, Nylen K, Csajbok L, Ohrfelt A, Tullberg M, Wikkelso C . Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006; 67(9):1600-4. DOI: 10.1212/01.wnl.0000242732.06714.0f. View

Shahim P, Politis A, Van der Merwe A, Moore B, Ekanayake V, Lippa S . Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology. 2020; 95(6):e623-e636. PMC: 7455355. DOI: 10.1212/WNL.0000000000009985. View

Starmark J, Stalhammar D, Holmgren E . The Reaction Level Scale (RLS85). Manual and guidelines. Acta Neurochir (Wien). 1988; 91(1-2):12-20. DOI: 10.1007/BF01400521. View

Sowers J, Wu P, Zhang K, DeWitt D, Prough D . Proteomic changes in traumatic brain injury: experimental approaches. Curr Opin Neurol. 2018; 31(6):709-717. PMC: 6221404. DOI: 10.1097/WCO.0000000000000613. View

10.

Al Nimer F, Thelin E, Nystrom H, Dring A, Svenningsson A, Piehl F . Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS One. 2015; 10(7):e0132177. PMC: 4489843. DOI: 10.1371/journal.pone.0132177. View

11.

Raheja A, Sinha S, Samson N, Bhoi S, Subramanian A, Sharma P . Serum biomarkers as predictors of long-term outcome in severe traumatic brain injury: analysis from a randomized placebo-controlled Phase II clinical trial. J Neurosurg. 2016; 125(3):631-41. DOI: 10.3171/2015.6.JNS15674. View

12.

Vos P, Lamers K, Hendriks J, van Haaren M, Beems T, Zimmerman C . Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. 2004; 62(8):1303-10. DOI: 10.1212/01.wnl.0000120550.00643.dc. View

13.

Nylen K, Ost M, Csajbok L, Nilsson I, Blennow K, Nellgard B . Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci. 2005; 240(1-2):85-91. DOI: 10.1016/j.jns.2005.09.007. View

14.

Thelin E, Al Nimer F, Frostell A, Zetterberg H, Blennow K, Nystrom H . A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. J Neurotrauma. 2019; 36(20):2850-2862. PMC: 6761606. DOI: 10.1089/neu.2019.6375. View

15.

Crouchman M, Rossiter L, Colaco T, Forsyth R . A practical outcome scale for paediatric head injury. Arch Dis Child. 2001; 84(2):120-4. PMC: 1718639. DOI: 10.1136/adc.84.2.120. View

16.

Park J, Bae Y, Kim J, Jung W, Choi J, Roh T . Glymphatic system evaluation using diffusion tensor imaging in patients with traumatic brain injury. Neuroradiology. 2022; 65(3):551-557. DOI: 10.1007/s00234-022-03073-x. View

17.

Peters A, Schnell E, Saugstad J, Treggiari M . Longitudinal Course of Traumatic Brain Injury Biomarkers for the Prediction of Clinical Outcomes: A Review. J Neurotrauma. 2021; 38(18):2490-2501. DOI: 10.1089/neu.2020.7448. View

18.

Lepinoux-Chambaud C, Eyer J . Review on intermediate filaments of the nervous system and their pathological alterations. Histochem Cell Biol. 2013; 140(1):13-22. DOI: 10.1007/s00418-013-1101-1. View

19.

Teasdale G, Jennett B . Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974; 2(7872):81-4. DOI: 10.1016/s0140-6736(74)91639-0. View

20.

Steyerberg E, Mushkudiani N, Perel P, Butcher I, Lu J, McHugh G . Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. PLoS Med. 2008; 5(8):e165. PMC: 2494563. DOI: 10.1371/journal.pmed.0050165. View